Transferring Immunotherapy Treatment to Another Centre — What Moves With You, and What Does Not

Yes. Immunotherapy can be transferred at any point in a course, and the decision is yours. No hospital owns a patient. No permission has to be granted. Asking for copies of your own reports is a routine administrative request. What needs planning is the handover and the timing — never the right to move.

This happens constantly and almost nobody documents it. A family relocates for work. A course that looked affordable at cycle two stops being affordable at cycle eight. A daughter abroad reads the plan and wants it reviewed. Confidence quietly drains away after a difficult few weeks. All of these are ordinary, and none of them require anyone’s approval. What families are rarely told is that a transfer is mostly an information problem: your treatment is only as portable as the records that describe it.

It is also worth separating two things that get confused. A second opinion is a review of the plan by another oncologist. A transfer is a change in who delivers it. Many families take an opinion, are told the plan is reasonable, and stay exactly where they are — which is a good outcome, not a wasted trip. You can read how a remote review works in Online and Remote Second Opinions for Immunotherapy before deciding whether anything needs to change at all.

Ten things. The written treatment summary, the pathology report, the biomarker report, the baseline and later scans as image files, the full cycle and dose record, the blood-test trend, the history of any immune side effect and its steroid treatment, your current medicines, the scheme and insurance paperwork, and the treating doctor’s contact.

The single most common failure is arriving with reports but not images. A typed radiology report describes a scan; it is not the scan. Response assessment on immunotherapy is a comparison, and a new radiologist who cannot see the baseline pictures is being asked to judge a change with only one half of it.

Keep two copies of everything: one paper set in a folder and one scanned set on a phone or in cloud storage. The scanned set is what makes a 2am presentation at an unfamiliar hospital manageable, and it is what lets a relative abroad read the plan the same evening.

The move itself is not the risk. The risk sits in the gap and in the missing history. An unplanned delay to the next cycle, a baseline scan the new radiologist cannot see, and an immune side effect nobody recorded are the three things that turn a routine transfer into a genuine clinical problem.

• An unplanned gap between cycles. Whether a delay matters, and how much, is a clinical judgement for an oncologist who knows your case — not something a records desk should decide by being slow. Book the new appointment before you stop attending the old one.
• Losing scan comparability. If the baseline images do not travel, the next scan is being read on its own. That can mean a repeat scan at your cost, or a less confident answer about whether treatment is working.
• The immune-event history disappearing. A past episode of colitis, hepatitis, pneumonitis or a hormone problem changes what can safely be given next and how closely you are watched. If it is not in the papers, for the new team it did not happen.
• Monitoring baselines resetting. A new centre without your earlier thyroid, liver and kidney results has no trend to compare against, so early drift may be read as normal for you when it is not.
• Scheme and insurance restarting. Pre-authorisation and empanelment are generally tied to the treating hospital, so approvals do not simply follow you. Ask both the new centre’s scheme desk and your insurer separately, and get each answer dated.
• Supply and pharmacy continuity. Counterfeit checkpoint inhibitors have been reported entering the Indian market. Have the medicine dispensed by the new hospital’s pharmacy and appear on the bill with a batch number, and decline any arrangement that routes a cold-chain drug outside it.

None of this is an argument against moving. Families move for good reasons, and staying somewhere that cannot manage what goes wrong is its own risk. It is an argument for moving deliberately: records first, appointment booked, next cycle protected. For accuracy about our own service line — at CION, immunotherapy is administered as day care, response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION and is billed by them, and CION does not provide CAR-T or cell therapy. Ask any centre you are considering to be equally specific about what it does itself and what it sends out.

In seven steps, in this order. Get the new opinion before you stop anything. Request the written summary. Collect the images. Ask where the block is. Time the move between cycles. Restart the scheme paperwork. Tell the old team in writing and keep the door open behind you.

1. 1

   Book the new centre’s opinion before you stop attending the old one

   Nothing needs to be cancelled to get a review. Going in this order means you never find yourself between centres with a cycle due and no one responsible for it.

2. 2

   Ask your treating oncologist for a written treatment summary

   Ask for it as a routine request rather than an announcement. It should name the diagnosis, the drug, the dose, every cycle date, anything held or stopped, and why.

3. 3

   Collect the imaging as image files, not only reports

   Go to each imaging centre with an ID and ask for a CD or USB of the baseline scan and every scan since. Check the disc opens before you leave the counter.

4. 4

   Find out where the paraffin block and slides are stored

   Even if nothing more is being tested today, knowing which laboratory holds the block saves a difficult search later if further biomarker testing is needed.

5. 5

   Time the move to fall between cycles

   The usable window is after a completed cycle, with the next one already booked at the new centre. If a hold or a steroid taper is in progress, ask the current oncologist before changing anything.

6. 6

   Restart the scheme and insurance paperwork at the new centre

   Approvals are generally tied to the treating hospital. Take your bills, the earlier authorisation and the policy documents, and ask the new scheme desk and your insurer separately for a dated position.

7. 7

   Tell the old team in writing, and keep the channel open

   A short written note keeps the relationship civil and makes it far easier to ask for a missing report later. You may also want their view on the record if something happens at 2am.

If the new plan differs materially from the old one, it is reasonable to ask whether your case can be discussed by a multidisciplinary team rather than by one doctor alone. What Is a Tumour Board and Was Your Case Discussed? explains what that meeting is and how to ask whether yours went to one.

Relocation, cost, lost confidence, a centre that cannot manage side effects locally, a relative abroad who wants a review, and a specialised therapy that has been suggested. Each of these needs a different first step, and only two of the six actually end in a transfer.

Where funding is coming from a family member overseas, the questions of cost, capability and travel tend to arrive together. Should You Go Abroad for Immunotherapy? works through when travelling for treatment genuinely changes what is available and when it mostly changes the bill.

Then what you need is a referral, not a transfer. CAR-T and other cell therapies are not the same thing as checkpoint-inhibitor immunotherapy, and in India they are delivered by a small number of accredited centres. CION does not provide CAR-T or cell therapy and does not stock CAR-T products.

The practical difference is the machinery around the treatment. A checkpoint inhibitor is an antibody given as a day-care infusion and you go home the same day. CAR-T involves collecting a patient’s own immune cells, having them modified in a manufacturing facility, and giving them back under inpatient monitoring, because the reactions that can follow — including cytokine release syndrome and neurological effects — have to be managed on site and at speed. Accreditation, not enthusiasm, decides which centres can offer it.

Our role here is orientation and onward referral: explaining what is involved, what to ask an accredited centre, and helping your records reach it in a usable form. Nothing on this page should be read as CION administering, stocking or arranging CAR-T product. If any centre presents cell therapy as routinely available, ask which accreditation it holds and ask to see it.

Most families who consider a transfer are really asking one of three questions: is this plan right, is somewhere else genuinely better, and was my case properly discussed. These pages take each of those on directly, so the decision to move or stay is made on information rather than on frustration.

• Online and Remote Second Opinions for Immunotherapy — how a review of your reports works without travelling, what to send, and what an opinion can and cannot settle.
• Should You Go Abroad for Immunotherapy? — when travelling changes what treatment is actually available, and when it mostly changes the cost. Particularly relevant where a relative overseas is funding care.
• What Is a Tumour Board and Was Your Case Discussed? — what a multidisciplinary meeting is, and how to ask whether your case went to one before the plan was set.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring between cycles and cost counselling fit together as one pathway.

Ask for Your Records Before You Decide

Requesting copies of your own reports is routine, and it commits you to nothing. A centre confident in its plan will hand them over without friction.